JP2015532096A5 - - Google Patents

Download PDF

Info

Publication number
JP2015532096A5
JP2015532096A5 JP2015534771A JP2015534771A JP2015532096A5 JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5 JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015534771 A JP2015534771 A JP 2015534771A JP 2015532096 A5 JP2015532096 A5 JP 2015532096A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
aoi
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534771A
Other languages
English (en)
Japanese (ja)
Other versions
JP6351598B2 (ja
JP2015532096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062410 external-priority patent/WO2014055370A1/en
Publication of JP2015532096A publication Critical patent/JP2015532096A/ja
Publication of JP2015532096A5 publication Critical patent/JP2015532096A5/ja
Application granted granted Critical
Publication of JP6351598B2 publication Critical patent/JP6351598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534771A 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法 Active JP6351598B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708554P 2012-10-01 2012-10-01
US61/708,554 2012-10-01
PCT/US2013/062410 WO2014055370A1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins

Publications (3)

Publication Number Publication Date
JP2015532096A JP2015532096A (ja) 2015-11-09
JP2015532096A5 true JP2015532096A5 (https=) 2016-11-17
JP6351598B2 JP6351598B2 (ja) 2018-07-04

Family

ID=49354940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534771A Active JP6351598B2 (ja) 2012-10-01 2013-09-27 糖タンパク質を産生するための組成物および方法

Country Status (28)

Country Link
US (2) US20150259425A1 (https=)
EP (1) EP2904092B1 (https=)
JP (1) JP6351598B2 (https=)
KR (1) KR102182885B1 (https=)
CN (1) CN104797707A (https=)
AU (1) AU2013327681B2 (https=)
BR (1) BR112015007319B1 (https=)
CA (1) CA2886753C (https=)
CY (1) CY1119602T1 (https=)
DK (1) DK2904092T3 (https=)
EA (1) EA201590550A1 (https=)
ES (1) ES2646594T3 (https=)
HK (1) HK1207394A1 (https=)
HR (1) HRP20171753T1 (https=)
HU (1) HUE034896T2 (https=)
IL (1) IL237916A0 (https=)
IN (1) IN2015DN02630A (https=)
LT (1) LT2904092T (https=)
ME (1) ME02882B (https=)
MX (1) MX366106B (https=)
NO (1) NO2760138T3 (https=)
PL (1) PL2904092T3 (https=)
PT (1) PT2904092T (https=)
RS (1) RS56641B1 (https=)
SG (2) SG10201702448WA (https=)
SI (1) SI2904092T1 (https=)
SM (1) SMT201700588T1 (https=)
WO (1) WO2014055370A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
AU2015339012B2 (en) * 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
CA3010600A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
CN109153716A (zh) * 2016-01-06 2019-01-04 安口生物公司 调节单克隆抗体组合物中的非岩藻糖基化物类
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CN108925137A (zh) * 2016-02-22 2018-11-30 新加坡科技研究局 细胞培养基
CN110121359A (zh) * 2016-11-11 2019-08-13 怀特黑德生物制剂研究所 人血浆培养基
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CN112566643A (zh) 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
EA202192860A1 (ru) * 2019-04-18 2021-12-23 Янссен Байотек, Инк Сиалилированные гликопротеины
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1360314B1 (en) * 2001-02-15 2009-01-14 Centocor, Inc. Chemically defined medium for cultured mammalian cells
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
DK1755659T3 (da) 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies

Similar Documents

Publication Publication Date Title
JP2015532096A5 (https=)
HRP20171753T1 (hr) Pripravci i postupci za proizvodnju glikoproteina
EA201900326A1 (ru) Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами
SG11201901495YA (en) Method for producing antibody fusion protein
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
EA202091422A1 (ru) Способ непрерывного производства продуктов на основе биспецифических антител
JP2011525355A5 (https=)
JP2012143232A5 (https=)
JP2013517776A5 (https=)
HRP20191409T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
MY169935A (en) "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
MX2015000683A (es) Metodo para producir moleculas monomericas y multimericas y uso de las mismas.
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ596595A (en) Method for orthopoxvirus production and purification
WO2010013947A3 (ko) 자연살해세포의 증식방법
NZ597742A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
JP2017508523A5 (https=)
WO2015010118A3 (en) Transthyretin amyloid-selective and polyreactive catabodies
HRP20231139T1 (hr) Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
JP2017520531A5 (https=)
MY184072A (en) Increasing virus like particle yield in plants
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.